Neuroendocrine Carcinoma Treatment Market is expected to reach US$ 2.9 Billion by 2029, at a CAGR of 8.0% | FMI

The Global Neuroendocrine Carcinoma Treatment Market is expected to reach US$ 1.7 Billion in 2022 with a CAGR of 8.0%, indicating favourable market growth during the projected period.

According to Future Market Insights, the market for somatostatin analogs as a therapy type is predicted to reach US$ 1.0 billion in 2022, accounting for more than half of the market for neuroendocrine carcinoma treatments.

Prominently driven by collaborative strategies for speedy research of drugs for neuroendocrine carcinoma treatment, the market is set for an impressive growth during the forecast period. Rising number of patients diagnosed with neuroendocrine carcinoma, increasing number of patients seeking treatment, and innovative drugs under clinical trials, along with research grants from government agencies are expected to boost the growth of the neuroendocrine carcinoma treatment market during the forecast period.

Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1278

In June 2019, Progenics Pharmaceuticals presented long-term follow up data from its pivotal phase 2 study of Azdera, which showed overall survival of 73.1% at two years and 44.2% at four years, improving the overall survival rate in patients suffering from neuroendocrine carcinoma.

Key Takeaways of Neuroendocrine Carcinoma Treatment Market Study

• Owing to large patient pool seeking treatment for gastric neuroendocrine tumors, the segment is expected to dominate the neuroendocrine carcinoma treatment market.
• Somatostatin analog therapy for vasoactive intestinal peptide, carcinoid tumors, pituitary adenomas, and other indications is expected to gain traction over targeted therapy and chemotherapy during the forecast period.
• Hospitals remain prominent end users as compared to clinics, as hospitalization of patients is required to monitor the progress of therapy deployed during the treatment of neuroendocrine carcinoma.
• North America is expected dominate the global neuroendocrine carcinoma treatment market, owing to improved healthcare infrastructure, favorable reimbursement scenario, increasing research grants, and large target patient pool.

Carcinoid tumor treatment market is a rare and aggressive type of cancer that affects the neuroendocrine cells in the body. The treatment for NEC depends on various factors, including the location, size, and stage of the tumor, as well as the patient’s overall health and medical history.

Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1278

Neuroendocrine Carcinoma Drug Manufacturers Focusing on Collaborations to Gain Competitive Advantage

AbbVie Inc., Advanced Accelerator Applications, and F. Hoffmann-La Roche are among the leading manufacturers that operate in the neuroendocrine carcinoma treatment market. In December 2019, AbbVie and Scripps Research announced a collaboration to develop a broad range of new therapeutics in the areas of oncology, immunology, neurology, and fibrosis. This strategic move is expected to cater to the needs of patients by innovating refined novel medicines. Eisai’s Levinima was approved in combination with Novartis’s Afinitor for the treatment of advanced renal cell carcinoma, in May 2016. This collaboration agreement has set the terms, whereby the sales teams from both pharmaceutical companies will promote the availability of this combination regimen to health service providers. In November 2017, VBL Therapeutics and NanoCarrier Co., Ltd. signed an exclusive agreement for VB-111 for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan. In December 2018, Advanced Accelerator Applications entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical Co. to develop and commercialize radiolabeled molecules for oncology indications.

Key Companies Profiled

• Pfizer Inc.
• Novartis AG
• Chiasma Inc.
• Ipsen
• Abbvie Inc.
• Valeant Pharmaceuticals International Inc.
• Jubilant Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd
• Advanced Accelerator Applications
• Mateon Therapeutics, Inc.
• Lexicon Pharmaceuticals, Inc.
• Isotopen Technologien München AGGlobal
• Hutchison China MediTech Ltd
• Amgen Inc
• Celgene Corporation

For more Report Customization, connect with us @ https://www.futuremarketinsights.com/customization-available/rep-gb-1278

Neuroendocrine Carcinoma Treatment Market by Category

By Indication:

• Gastric Neuroendocrine Tumors
• Lung Neuroendocrine Tumors
• Pancreatic Neuroendocrine Tumors
• Appendicular Neuroendocrine Tumors

By Treatment Type:

• Somatostatin Analogs
• Targeted Therapy
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
• Chemotherapy
  • Antimetabolites
  • Alkylating Agents
  • Natural Products

By End User:

• Hospitals
• Clinics
• Oncology Centers
• Ambulatory Surgery Centers

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs